Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T‐cell lymphoma

29 Oct 2009

Abstract excerpt

Romidepsin has shown promise in the treatment of T-cell lymphomas, and so we evaluated molecular endpoints gathered from 61 patients enrolled on a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma at the National Institutes of Health. The endpoints included histone H3 acetylation and ABCB1 gene expression in peripheral blood mononuclear cells (PBMCs); ABCB1 gene expression in tumour biopsy...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Histone Deacetylase Inhibitors Research
Share to Peptidase Inhibition and Analysis
Share to Viral-associated cancers and disorders

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 19874311
DOI: 10.1111/j.1365-2141.2009.07954.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T‐cell lymphomaPMID 19874311Read ↗

Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumorsSemantic proximity Read ↗

Romidepsin in peripheral and cutaneous T‐cell lymphoma: mechanistic implications from clinical and correlative dataSemantic proximity Read ↗

Romidepsin for the treatment of cutaneous T-cell lymphomaSemantic proximity Read ↗

Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma.Semantic proximity Read ↗

Electrocardiographic studies of romidepsin demonstrate its safety and identify a potential role for K(ATP) channel.Semantic proximity Read ↗

Romidepsin and Azacitidine Synergize in their Epigenetic Modulatory Effects to Induce Apoptosis in CTCLSemantic proximity Read ↗

Phase II trial of romidepsin as consolidation therapy after gemcitabine, dexamethasone, and cisplatin in elderly transplant-ineligible patients with relapsed/refractory peripheral T- cell lymphomaSemantic proximity Read ↗

Real-world experience of combined treatment with azacitidine and romidepsin in patients with peripheral T-cell lymphomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.